Figure 5
From: Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
Pneumocystis prophylaxis has a beneficial effect on the overall first-year survival rate in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma patients.
